tiprankstipranks
Advertisement
Advertisement

PHAR Stock Latest News

Buy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained
RatingsBuy Rating Reaffirmed on Joenja’s European Expansion and Pediatric FDA Catalyst; $37 Price Target Maintained
16d ago
PHAR
Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
PremiumRatings
Pharming: Profitable Core, Advancing Pipeline Underpin Buy Rating and Maintained $37 Price Target
29d ago
PHAR
Pharming Wins FDA Review for Joenja Pediatric sNDA in APDS
PremiumCompany Announcements
Pharming Wins FDA Review for Joenja Pediatric sNDA in APDS
2M ago
6K
PHAR
Pharming Group appoints KPMG as new auditor as shareholders back full AGM agenda
PremiumCompany Announcements
Pharming Group appoints KPMG as new auditor as shareholders back full AGM agenda
2M ago
6K
PHAR
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
PremiumRatings
Pantginis Reiterates Buy on Pharming as Joenja’s Global Expansion Advances; $37 Price Target Maintained
2M ago
PHAR
Pharming Wins EU Green Light for Joenja, First Approved Treatment for APDS
PremiumCompany AnnouncementsPharming Wins EU Green Light for Joenja, First Approved Treatment for APDS
2M ago
6K
PHAR
Pharming’s Joenja granted marketing authorization by European Commission
Premium
The Fly
Pharming’s Joenja granted marketing authorization by European Commission
2M ago
PHAR
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026
2M ago
IVA
ATAI
Pharming price target lowered to $40 from $41 at Oppenheimer
PremiumThe Fly
Pharming price target lowered to $40 from $41 at Oppenheimer
2M ago
PHAR
Pharming reports Q1 EPS 1c, consensus 0c
PremiumThe Fly
Pharming reports Q1 EPS 1c, consensus 0c
3M ago
PHAR
Pharming sees FY26 revenue $405M-$425M, consensus $411.9M
PremiumThe Fly
Pharming sees FY26 revenue $405M-$425M, consensus $411.9M
3M ago
PHAR
Pharming Posts Mixed Q1 2026 as Joenja® Growth Offsets RUCONEST® Decline and Global Label Expansion Advances
PremiumCompany Announcements
Pharming Posts Mixed Q1 2026 as Joenja® Growth Offsets RUCONEST® Decline and Global Label Expansion Advances
3M ago
6K
PHAR
Pharming Group Showcases New Leniolisib Data and Expands Immunology Focus at CIS 2026
PremiumCompany AnnouncementsPharming Group Showcases New Leniolisib Data and Expands Immunology Focus at CIS 2026
3M ago
6K
PHAR
Pharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on Agenda
Premium
Company Announcements
Pharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on Agenda
3M ago
6K
PHAR
Pharming initiated with a Buy at Canaccord on growth potential
Premium
The Fly
Pharming initiated with a Buy at Canaccord on growth potential
3M ago
PHAR
Pharming initiated with a Buy at Canaccord
PremiumThe Fly
Pharming initiated with a Buy at Canaccord
3M ago
PHAR
Pharming Group Files 2025 Annual Report and Form 20-F
PremiumCompany Announcements
Pharming Group Files 2025 Annual Report and Form 20-F
4M ago
6K
PHAR
Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
PremiumCompany Announcements
Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
4M ago
6K
PHAR
Pharming announces approval of Joenja in Japan for patients aged 4 years and old
PremiumThe Fly
Pharming announces approval of Joenja in Japan for patients aged 4 years and old
4M ago
PHAR
Pharming Group Wins Landmark Japan Approval for Joenja in Pediatric and Adult APDS
PremiumCompany AnnouncementsPharming Group Wins Landmark Japan Approval for Joenja in Pediatric and Adult APDS
4M ago
6K
PHAR
Pharming price target lowered to $41 from $42 at Oppenheimer
Premium
The Fly
Pharming price target lowered to $41 from $42 at Oppenheimer
4M ago
PHAR
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
Premium
Ratings
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
4M ago
PHAR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >